{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:51:48Z","timestamp":1784638308399,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Institute of Health","award":["K01AG068365"],"award-info":[{"award-number":["K01AG068365"]}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["1-25-PDF-66"],"award-info":[{"award-number":["1-25-PDF-66"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40264-025-01629-3","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T08:46:39Z","timestamp":1764233199000},"page":"471-480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Medications Associated with Increased Risk of Hypoglycemia in Older Adults on Sulfonylureas: A High-Throughput Case-Crossover-Based Screening Study"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2622-6553","authenticated-orcid":false,"given":"Sungho","family":"Bea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Patorno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.","family":"Wexler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3336-5412","authenticated-orcid":false,"given":"Katsiaryna","family":"Bykov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"1629_CR1","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice C. 13. Older Adults: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S266\u2013S82.","DOI":"10.2337\/dc25-S013"},{"issue":"16","key":"1629_CR2","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","volume":"370","author":"EW Gregg","year":"2014","unstructured":"Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, et al. Changes in diabetes-related complications in the United States, 1990\u20132010. N Engl J Med. 2014;370(16):1514\u201323.","journal-title":"N Engl J Med"},{"issue":"12","key":"1629_CR3","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1111\/jgs.12035","volume":"60","author":"MS Kirkman","year":"2012","unstructured":"Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older adults: a consensus report. J Am Geriatr Soc. 2012;60(12):2342\u201356.","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"1629_CR4","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1007\/s40520-022-02165-1","volume":"34","author":"F Remelli","year":"2022","unstructured":"Remelli F, Ceresini MG, Trevisan C, Noale M, Volpato S. Prevalence and impact of polypharmacy in older patients with type 2 diabetes. Aging Clin Exp Res. 2022;34(9):1969\u201383.","journal-title":"Aging Clin Exp Res"},{"issue":"7","key":"1629_CR5","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1111\/jgs.14870","volume":"65","author":"SE Merel","year":"2017","unstructured":"Merel SE, Paauw DS. Common drug side effects and drug-drug interactions in elderly adults in primary care. J Am Geriatr Soc. 2017;65(7):1578\u201385.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"1629_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/dme.13859","volume":"36","author":"AJ Sinclair","year":"2019","unstructured":"Sinclair AJ, Abdelhafiz AH, Forbes A, Munshi M. Evidence-based diabetes care for older people with type 2 diabetes: a critical review. Diabet Med. 2019;36(4):399\u2013413.","journal-title":"Diabet Med"},{"issue":"1","key":"1629_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2337\/diaspect.27.1.20","volume":"27","author":"BJ Gates","year":"2014","unstructured":"Gates BJ, Walker KM. Physiological changes in older adults and their effect on diabetes treatment. Diabetes Spectr. 2014;27(1):20\u20138.","journal-title":"Diabetes Spectr"},{"key":"1629_CR8","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice C. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S181\u2013S206.","DOI":"10.2337\/dc25-S009"},{"issue":"1","key":"1629_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12877-022-02792-3","volume":"22","author":"K DeCarlo","year":"2022","unstructured":"DeCarlo K, Wallia A, Kang RH, Cooper A, Cherupally M, Harris SA, et al. Initiating second-line antidiabetic medication among older adults with type 2 diabetes on Metformin. BMC Geriatr. 2022;22(1):97.","journal-title":"BMC Geriatr"},{"issue":"12","key":"1629_CR10","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1056\/NEJMoa2200433","volume":"387","author":"DM Nathan","year":"2022","unstructured":"Group GSR, Nathan DM, Lachin JM, Balasubramanyam A, Burch HB, Buse JB, et al. Glycemia reduction in type 2 diabetes\u2014glycemic outcomes. N Engl J Med. 2022;387(12):1063\u201374.","journal-title":"N Engl J Med"},{"issue":"2","key":"1629_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/2042018816638050","volume":"7","author":"M May","year":"2016","unstructured":"May M, Schindler C. Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016;7(2):69\u201383.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"7","key":"1629_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2165\/00002018-200528070-00004","volume":"28","author":"AJ Scheen","year":"2005","unstructured":"Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf. 2005;28(7):601\u201331.","journal-title":"Drug Saf"},{"issue":"1","key":"1629_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1365-2125.2005.02379.x","volume":"60","author":"A Holstein","year":"2005","unstructured":"Holstein A, Plaschke A, Ptak M, Egberts EH, El-Din J, Brockmoller J, et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol. 2005;60(1):103\u20136.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1629_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/clpt.2009.176","volume":"87","author":"K Zhou","year":"2010","unstructured":"Zhou K, Donnelly L, Burch L, Tavendale R, Doney AS, Leese G, et al. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clin Pharmacol Ther. 2010;87(1):52\u20136.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1629_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.2337\/diaspect.19.4.202","volume":"19","author":"C Triplitt","year":"2006","unstructured":"Triplitt C. Drug interactions of medications commonly used in diabetes. Diabetes Spectr. 2006;19(4):202\u201311.","journal-title":"Diabetes Spectr"},{"issue":"7","key":"1629_CR16","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1093\/ndt\/gft462","volume":"29","author":"P Arnouts","year":"2014","unstructured":"Arnouts P, Bolignano D, Nistor I, Bilo H, Gnudi L, Heaf J, et al. Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties. Nephrol Dial Transplant. 2014;29(7):1284\u2013300.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1629_CR17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/cpt.1376","volume":"106","author":"K Bykov","year":"2019","unstructured":"Bykov K, Schneeweiss S, Glynn RJ, Mittleman MA, Gagne JJ. A case-crossover-based screening approach to identifying clinically relevant drug-drug interactions in electronic healthcare data. Clin Pharmacol Ther. 2019;106(1):238\u201344.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1629_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70088","volume":"34","author":"C Chen","year":"2025","unstructured":"Chen C, Pham Nguyen TP, Hughes JE, Hennessy S, Leonard CE, Miano TA, et al. Evaluation of drug-drug interactions in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf. 2025;34(1):e70088.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"1629_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70071","volume":"34","author":"SH Bots","year":"2025","unstructured":"Bots SH, Brown J, Wong AYS, Martin I, Douglas I, Klungel OH, et al. Core concepts: self-controlled designs in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2025;34(1):e70071.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1629_CR20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/oxfordjournals.aje.a115853","volume":"133","author":"M Maclure","year":"1991","unstructured":"Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133(2):144\u201353.","journal-title":"Am J Epidemiol"},{"issue":"6","key":"1629_CR21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/joim.12186","volume":"275","author":"J Hallas","year":"2014","unstructured":"Hallas J, Pottegard A. Use of self-controlled designs in pharmacoepidemiology. J Intern Med. 2014;275(6):581\u20139.","journal-title":"J Intern Med"},{"issue":"5","key":"1629_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/pds.4712","volume":"28","author":"JY Min","year":"2019","unstructured":"Min JY, Presley CA, Wharton J, Griffin MR, Greevy RA Jr., Hung AM, et al. Accuracy of a composite event definition for hypoglycemia. Pharmacoepidemiol Drug Saf. 2019;28(5):625\u201331.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"1629_CR23","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.2337\/dc18-2154","volume":"42","author":"AJ Karter","year":"2019","unstructured":"Karter AJ, Warton EM, Moffet HH, Ralston JD, Huang ES, Miller DR, et al. Revalidation of the hypoglycemia risk stratification tool using ICD-10 codes. Diabetes Care. 2019;42(4):e58\u20139.","journal-title":"Diabetes Care"},{"issue":"11","key":"1629_CR24","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1002\/pds.3508","volume":"22","author":"GP Consiglio","year":"2013","unstructured":"Consiglio GP, Burden AM, Maclure M, McCarthy L, Cadarette SM. Case-crossover study design in pharmacoepidemiology: systematic review and recommendations. Pharmacoepidemiol Drug Saf. 2013;22(11):1146\u201353.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"31","key":"1629_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2017.167","volume":"4","author":"KJ Quinn","year":"2017","unstructured":"Quinn KJ, Shah NH. A dataset quantifying polypharmacy in the United States. Sci Data. 2017;4(31):170167.","journal-title":"Sci Data"},{"issue":"303","key":"1629_CR26","first-page":"690","volume":"58","author":"N Mantel","year":"1963","unstructured":"Mantel N. Chi-square tests with one degree of freedom; extensions of the Mantel\u2013Haenszel procedure. J Am Stat Assoc. 1963;58(303):690\u2013700.","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"1629_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF02295996","volume":"12","author":"NQ Mc","year":"1947","unstructured":"Mc NQ. Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika. 1947;12(2):153\u20137.","journal-title":"Psychometrika"},{"issue":"6","key":"1629_CR28","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/EDE.0000000000001087","volume":"30","author":"K Bykov","year":"2019","unstructured":"Bykov K, Franklin JM, Li H, Gagne JJ. Comparison of self-controlled designs for evaluating outcomes of drug-drug interactions: simulation study. Epidemiology. 2019;30(6):861\u20136.","journal-title":"Epidemiology"},{"issue":"3","key":"1629_CR29","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/EDE.0b013e31828ac9cb","volume":"24","author":"SV Wang","year":"2013","unstructured":"Wang SV, Gagne JJ, Glynn RJ, Schneeweiss S. Case-crossover studies of therapeutics: design approaches to addressing time-varying prognosis in elderly populations. Epidemiology. 2013;24(3):375\u20138.","journal-title":"Epidemiology"},{"key":"1629_CR30","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice C. 6. Glycemic goals and hypoglycemia: standards of care in diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S128\u2013S45.","DOI":"10.2337\/dc25-S006"},{"issue":"367","key":"1629_CR31","first-page":"4255","volume":"2009","author":"Y Benjamini","year":"1906","unstructured":"Benjamini Y, Heller R, Yekutieli D. Selective inference in complex research. Philos Trans A Math Phys Eng Sci. 1906;2009(367):4255\u201371.","journal-title":"Philos Trans A Math Phys Eng Sci."},{"issue":"3","key":"1629_CR32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/1467-9868.00346","volume":"64","author":"JD Storey","year":"2002","unstructured":"Storey JD. A direct approach to false discovery rates. J R Stat Soc Series B Stat Methodol. 2002;64(3):479\u201398.","journal-title":"J R Stat Soc Series B Stat Methodol"},{"issue":"10","key":"1629_CR33","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1001\/jamainternmed.2014.3293","volume":"174","author":"TM Parekh","year":"2014","unstructured":"Parekh TM, Raji M, Lin YL, Tan A, Kuo YF, Goodwin JS. Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas. JAMA Intern Med. 2014;174(10):1605\u201312.","journal-title":"JAMA Intern Med"},{"issue":"9","key":"1629_CR34","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/phar.2450","volume":"40","author":"S Lee","year":"2020","unstructured":"Lee S, Ock M, Kim HS, Kim H. Effects of co-administration of sulfonylureas and antimicrobial drugs on hypoglycemia in patients with type 2 diabetes using a case-crossover design. Pharmacotherapy. 2020;40(9):902\u201312.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"1629_CR35","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40264-019-00901-7","volume":"43","author":"KE Kennedy","year":"2020","unstructured":"Kennedy KE, Teng C, Patek TM, Frei CR. Hypoglycemia associated with antibiotics alone and in combination with sulfonylureas and meglitinides: an epidemiologic surveillance study of the FDA adverse event reporting system (FAERS). Drug Saf. 2020;43(4):363\u20139.","journal-title":"Drug Saf"},{"issue":"4","key":"1629_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0266471","volume":"17","author":"SH Liao","year":"2022","unstructured":"Liao SH, Hu SY, How CK, Hsieh VC, Chan CM, Chiu CS, et al. Risk for hypoglycemic emergency with levofloxacin use, a population-based propensity score matched nested case-control study. PLoS ONE. 2022;17(4):e0266471.","journal-title":"PLoS ONE"},{"issue":"3","key":"1629_CR37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.4065\/mcp.2009.0394","volume":"85","author":"M Egi","year":"2010","unstructured":"Egi M, Bellomo R, Stachowski E, French CJ, Hart GK, Taori G, et al. Hypoglycemia and outcome in critically ill patients. Mayo Clin Proc. 2010;85(3):217\u201324.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"1629_CR38","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/0002-9343(80)90250-8","volume":"68","author":"SI Miller","year":"1980","unstructured":"Miller SI, Wallace RJ Jr, Musher DM, Septimus EJ, Kohl S, Baughn RE. Hypoglycemia as a manifestation of sepsis. Am J Med. 1980;68(5):649\u201354.","journal-title":"Am J Med"},{"issue":"3","key":"1629_CR39","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/EDE.0000000000000638","volume":"28","author":"X Han","year":"2017","unstructured":"Han X, Chiang C, Leonard CE, Bilker WB, Brensinger CM, Li L, et al. Biomedical informatics approaches to identifying drug-drug interactions: application to insulin secretagogues. Epidemiology. 2017;28(3):459\u201368.","journal-title":"Epidemiology"},{"issue":"4","key":"1629_CR40","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1365-2796.2010.02257.x","volume":"268","author":"T Tirkkonen","year":"2010","unstructured":"Tirkkonen T, Heikkila P, Huupponen R, Laine K. Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide. J Intern Med. 2010;268(4):359\u201366.","journal-title":"J Intern Med"},{"key":"1629_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110531","volume":"130","author":"CE Leonard","year":"2020","unstructured":"Leonard CE, Brensinger CM, Pham Nguyen TP, Horn JR, Chung S, Bilker WB, et al. Screening to identify signals of opioid drug interactions leading to unintentional traumatic injury. Biomed Pharmacother. 2020;130:110531.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"1629_CR42","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/cpt.2717","volume":"112","author":"TA Miano","year":"2022","unstructured":"Miano TA, Wang L, Leonard CE, Brensinger CM, Acton EK, Dawwas GK, et al. Identifying clinically relevant drug-drug interactions with methadone and buprenorphine: a translational approach to signal detection. Clin Pharmacol Ther. 2022;112(5):1120\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"1629_CR43","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/pds.5031","volume":"29","author":"K Bykov","year":"2020","unstructured":"Bykov K, Wang SV, Hallas J, Pottegard A, Maclure M, Gagne JJ. Bias in case-crossover studies of medications due to persistent use: a simulation study. Pharmacoepidemiol Drug Saf. 2020;29(9):1079\u201385.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"1629_CR44","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1146\/annurev.publhealth.21.1.193","volume":"21","author":"M Maclure","year":"2000","unstructured":"Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health. 2000;21(1):193\u2013221.","journal-title":"Annu Rev Public Health"},{"issue":"6","key":"1629_CR45","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/14740338.2017.1325463","volume":"16","author":"M Arnaud","year":"2017","unstructured":"Arnaud M, Begaud B, Thurin N, Moore N, Pariente A, Salvo F. Methods for safety signal detection in healthcare databases: a literature review. Expert Opin Drug Saf. 2017;16(6):721\u201332.","journal-title":"Expert Opin Drug Saf"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01629-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01629-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01629-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:01:23Z","timestamp":1773939683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01629-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1629"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01629-3","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EP is\u00a0principal investigator\u00a0of a research grant to the Brigham and Women\u2019s Hospital from Boehringer Ingelheim, not related to the topic of this work. EP receives royalties from UpToDate. DJW reports consultancy for Novo Nordisk and serving as a data monitoring committee member for SOUL and FLOW trials. The remaining authors have no relevant conflicts of interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was obtained from the Brigham and Women's Hospital Institutional Review Board (IRB No. 2020P003686).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Patient-level data are not available for sharing due to data use agreements. Definitions and aggregate data are provided in the Supplement. Code and protocol are available from the corresponding author upon request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"KB conceptualized the study. KB, SB, and EP designed the study. GH provided statistical input and contributed to methodology. SB performed data curation and statistical analysis. All authors interpreted the data. SB and KB drafted the manuscript. EP, GH, JMP, and DJW critically revised the manuscript. All authors read and approved the final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}